The U.S. Food and Drug Administration (FDA) has announced it will reassess its approach to opioid medications, in an effort to reverse the epidemic of abuse. The plan comes in response to pressure from Congress, The New York Times reports.
FDA Deputy Commissioner for Medical Products and Tobacco Dr. Robert Califf said Thursday the agency will toughen its response to the opioid crisis, while still allowing patients in pain to have access to effective relief.
The agency said it will convene an expert panel before approving new opioids. It will toughen requirements to study drugs after they come to market, and increase access to pain management training for physicians and other prescribers.